Response to pathological processes in the peritoneal cavity-Sepsis, tumours, adhesions, and ascites

Seminars in Pediatric Surgery

Volumn 23, Issue 6, 2014, Pages 331-335

  Stommel, Martijn W J ^a   Strik, Chema ^a   van Goor, Harry ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adhesions; Ascites; Inflammatory response; Peritoneal metastasis; Peritoneum; Sepsis

Indexed keywords

ABDOMINAL ABSCESS; ARTICLE; ASCITES; HUMAN; INFLAMMATION; PEDIATRIC SURGERY; PERITONEUM ADHESION; PERITONEUM METASTASIS; PERITONEUM TUMOR; PERITONITIS; SEPSIS; TREATMENT INDICATION; PATHOLOGY; PERITONEAL CAVITY; TISSUE ADHESIONS;

ASCITES; HUMANS; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; PERITONITIS; SEPSIS; TISSUE ADHESIONS;

EID: 84918555372     PISSN: 10558586     EISSN: 15329453     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2014.06.003     Document Type: Article

References (84)

1. Sammour T., Kahokehr A., Soop M., Hill A.G. Peritoneal damage: the inflammatory response and clinical implications of the neuro-immuno-humoral axis. World J Surg 2010, 34(4):704-720.
2. Fanous M.Y., Phillips A.J., Windsor J.A. Mesenteric lymph: the bridge to future management of critical illness. JOP 2007, 8(4):374-399.
3. Michailova K.N., Usunoff K.G. Serosal membranes (pleura, pericardium, peritoneum). Normal structure, development and experimental pathology. Adv Anat Embryol Cell Biol 2006, 183:i-vii. [1-144, back cover].
4. Last M., Kurtz L., Stein T.A., Wise L. Effect of PEEP on the rate of thoracic duct lymph flow and clearance of bacteria from the peritoneal cavity. Am J Surg 1983, 145(1):126-130.
5. Semple J.W., Italiano J.E., Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011, 11(4):264-274.
6. Fernandes-Alnemri T., Yu J.W., Datta P., Wu J., Alnemri E.S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009, 458(7237):509-513.
7. Levi M., van der Poll T. Inflammation and coagulation. Crit Care Med 2010, 38(suppl 2):S26-S34.
8. Kuijpers A.M., Mirck B., Aalbers A.G., et al. Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 2013, 20(13):4224-4230.
9. Abraham S.N., John A.L. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010, 10(6):440-452.
10. Griffith D.E., Johnson A.R., Kumar A., Holiday D.B., Idell S. Growth factors for human pleural mesothelial cells in soluble products from formed clots. Thromb Res 1994, 74(3):207-218.
11. Eriksen M.T., Wibe A., Syse A., Haffner J., Wiig J.N., Norwegian Rectal Cancer G., Norwegian Gastrointestinal Cancer G. Inadvertent perforation during rectal cancer resection in Norway. Br J Surg 2004, 91(2):210-216.
12. Serhan C.N. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?. Am J Pathol 2010, 177(4):1576-1591.
13. Hellebrekers B.W., Emeis J.J., Kooistra T., et al. A role for the fibrinolytic system in postsurgical adhesion formation. Fertil Steril 2005, 83(1):122-129.
14. Holmdahl L. Making and covering of surgical footprints. Lancet 1999, 353(9163):1456-1457.
15. ten Broek R.P., Issa Y., van Santbrink E.J., et al. Burden of adhesions in abdominal and pelvic surgery: systematic review and met-analysis. Br Med J 2013, 347:f5588.
16. van Eijck F.C., Wijnen R.M., van Goor H. The incidence and morbidity of adhesions after treatment of neonates with gastroschisis and omphalocele: a 30-year review. J Pediatr Surg 2008, 43(3):479-483.
17. Ten Broek R.P., Stommel M.W., Strik C., van Laarhoven C.J., Keus F., van Goor H. Benefits and harms of adhesion barriers for abdominal surgery: a systematic review and meta-analysis. Lancet 2013.
18. Catena F., Ansaloni L., Di Saverio S., Pinna A.D. P.O.P.A. study: prevention of postoperative abdominal adhesions by icodextrin 4% solution after laparotomy for adhesive small bowel obstruction. A prospective randomized controlled trial. J Gastrointest Surg 2012, 16(2):382-388. World Society of Emergency Surgery.
19. Hellebrekers B.W., Trimbos-Kemper T.C., Boesten L., et al. Preoperative predictors of postsurgical adhesion formation and the prevention of adhesions with plasminogen activator (PAPA-study): results of a clinical pilot study. Fertil Steril 2009, 91(4):1204-1214.
20. Aarons C.B., Cohen P.A., Gower A., et al. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg 2007, 245(2):176-184.
21. Hellebrekers B.W., Kooistra T. Pathogenesis of postoperative adhesion formation. Br J Surg 2011, 98(11):1503-1516.
22. Dinarvand P., Farhadian S., Seyedjafari E., et al. Novel approach to reduce postsurgical adhesions to a minimum: administration of losartan plus atorvastatin intraperitoneally. J Surg Res 2013, 181(1):91-98.
23. Reed K.L., Fruin A.B., Gower A.C., Stucchi A.F., Leeman S.E., Becker J.M. A neurokinin 1 receptor antagonist decreases postoperative peritoneal adhesion formation and increases peritoneal fibrinolytic activity. Proc Natl Acad Sci U S A 2004, 101(24):9115-9120.
24. Esposito A.J., Heydrick S.J., Cassidy M.R., Gallant J., Stucchi A.F., Becker J.M. Substance P is an early mediator of peritoneal fibrinolytic pathway genes and promotes intra-abdominal adhesion formation. J Surg Res 2013, 181(1):25-31.
25. Buyne O.R., Bleichrodt R.P., Verweij P.E., Groenewoud H.M., van Goor H., Hendriks T. A peritonitis model with low mortality and persisting intra-abdominal abscesses. Int J Exp Pathol 2006, 87(5):361-368.
26. Hau T., Hoffman R., Simmons R.L. Mechanisms of the adjuvant effect of hemoglobin in experimental peritonitis. I. In vivo inhibition of peritoneal leukocytosis. Surgery 1978, 83(2):223-229.
27. Bakrin N., Bereder J.M., Decullier E., et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 2013.
28. Farthmann E.H., Schoffel U. Epidemiology and pathophysiology of intraabdominal infections (IAI). Infection 1998, 26(5):329-334.
29. van Goor H., de Graaf J.S., Grond J., et al. Fibrinolytic activity in the abdominal cavity of rats with faecal peritonitis. Br J Surg 1994, 81(7):1046-1049.
30. Wilkosz S., Ireland G., Khwaja N., et al. A comparative study of the structure of human and murine greater omentum. Anat Embryol (Berl) 2005, 209(3):251-261.
31. Platell C., Cooper D., Papadimitriou J.M., Hall J.C. The omentum. World J Gastroenterol 2000, 6(2):169-176.
32. Hall J.C., Heel K.A., Papadimitriou J.M., Platell C. The pathobiology of peritonitis. Gastroenterology 1998, 114(1):185-196.
33. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992, 101(6):1644-1655.
34. van Ruler O., Kiewiet J.J., van Ketel R.J., Boermeester M.A., Dutch Peritonitis Study G. Initial microbial spectrum in severe secondary peritonitis and relevance for treatment. Eur J Clin Microbiol Infect Dis 2012, 31(5):671-682.
35. Solomkin J.S., Mazuski J.E., Bradley J.S., et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010, 50(2):133-164.
36. Robledo F.A., Luque-de-Leon E., Suarez R., et al. Open versus closed management of the abdomen in the surgical treatment of severe secondary peritonitis: a randomized clinical trial. Surg Infect (Larchmt) 2007, 8(1):63-72.
37. Bjorck M, Wanhainen A. Management of abdominal compartment syndrome and the open abdomen. Eur J Vasc Endovasc Surg, 2014.
38. Runyon B.A. Care of patients with ascites. N Engl J Med 1994, 330(5):337-342.
39. Giefer M.J., Murray K.F., Colletti R.B. Pathophysiology, diagnosis, and management of pediatric ascites. J Pediatr Gastroenterol Nutr 2011, 52(5):503-513.
40. Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int 2012, 32(2):199-213.
41. La Villa G., Gentilini P. Hemodynamic alterations in liver cirrhosis. Mol Aspects Med 2008, 29(1-2):112-118.
42. Hennenberg M., Trebicka J., Kohistani A.Z., Heller J., Sauerbruch T. Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis. Eur J Clin Invest 2009, 39(10):906-913.
43. Fogel M.R., Sawhney V.K., Neal E.A., Miller R.G., Knauer C.M., Gregory P.B. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol 1981, 3(suppl 1):73-80.
44. Perez-Ayuso R.M., Arroyo V., Planas R., et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983, 84(5pt1):961-968.
45. Gines P., Arroyo V., Quintero E., et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987, 93(2):234-241.
46. Bernardi M., Caraceni P., Navickis R.J., Wilkes M.M. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 2012, 55(4):1172-1181.
47. Salerno F., Camma C., Enea M., Rossle M., Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007, 133(3):825-834.
48. Nagy J.A., Herzberg K.T., Dvorak J.M., Dvorak H.F. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 1993, 53(11):2631-2643.
49. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219(4587):983-985.
50. Feldman G.B., Knapp R.C., Order S.E., Hellman S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972, 32(8):1663-1666.
51. Pockros P.J., Esrason K.T., Nguyen C., Duque J., Woods S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992, 103(4):1302-1306.
52. Bellati F., Napoletano C., Ruscito I., et al. Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review. Invest New Drugs 2010, 28(6):887-894.
53. Mackey J.R., Wood L., Nabholtz J., Jensen J., Venner P. A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites. J Pain Symptom Manage 2000, 19(3):193-199.
54. Rath U., Kaufmann M., Schmid H., et al. Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991, 27(2):121-125.
55. Schilsky R.L., Choi K.E., Grayhack J., Grimmer D., Guarnieri C., Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 1990, 8(12):2054-2061.
56. Heiss M.M., Murawa P., Koralewski P., et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010, 127(9):2209-2221.
57. Gotlieb W.H., Amant F., Advani S., et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2012, 13(2):154-162.
58. Randle R.W., Swett K.R., Swords D.S., et al. Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 2013.
59. Facchiano E., Risio D., Kianmanesh R., Msika S. Laparoscopic hyperthermic intraperitoneal chemotherapy: indications, aims, and results: a systematic review of the literature. Ann Surg Oncol 2012, 19(9):2946-2950.
60. Valle M., Van der Speeten K., Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 2009, 100(4):331-334.
61. Alkhamesi N.A., Ziprin P., Pfistermuller K., Peck D.H., Darzi A.W. ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis 2005, 22(6):449-459.
62. Nakashio T., Narita T., Akiyama S., et al. Adhesion of human gastric and pancreatic cancer cells to peritoneal mesothelial cells is mediated by CD44 and beta(1) integrin. Int J Oncol 1997, 10(1):183-188.
63. Slack-Davis J.K., Atkins K.A., Harrer C., Hershey E.D., Conaway M. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 2009, 69(4):1469-1476.
64. Kawamura T., Endo Y., Yonemura Y., et al. Significance of integrin alpha2/beta1 in peritoneal dissemination of a human gastric cancer xenograft model. Int J Oncol 2001, 18(4):809-815.
65. Moser T.L., Pizzo S.V., Bafetti L.M., Fishman D.A., Stack M.S. Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. Int J Cancer 1996, 67(5):695-701.
66. Sorensen E.W., Gerber S.A., Sedlacek A.L., Rybalko V.Y., Chan W.M., Lord E.M. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res 2009, 45(2-3):185-194.
67. Brokelman W.J., Lensvelt M., Borel Rinkes I.H., Klinkenbijl J.H., Reijnen M.M. Peritoneal changes due to laparoscopic surgery. Surg Endosc 2011, 25(1):1-9.
68. Mochizuki Y., Nakanishi H., Kodera Y., et al. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 2004, 21(1):39-47.
69. Stadlmann S., Raffeiner R., Amberger A., et al. Disruption of the integrity of human peritoneal mesothelium by interleukin-1beta and tumor necrosis factor-alpha. Virchows Arch 2003, 443(5):678-685.
70. Casey R.C., Burleson K.M., Skubitz K.M., et al. Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 2001, 159(6):2071-2080.
71. Kobayashi H., Man S., Graham C.H., Kapitain S.J., Teicher B.A., Kerbel R.S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci U S A 1993, 90(8):3294-3298.
72. Sodek K.L., Ringuette M.J., Brown T.J. Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 2009, 124(9):2060-2070.
73. Olson M.F. Applications for ROCK kinase inhibition. Curr Opin Cell Biol 2008, 20(2):242-248.
74. Puls L.E., Duniho T., Hunter J.E., Kryscio R., Blackhurst D., Gallion H. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 1996, 61(1):109-112.
75. Miyamoto S., Hirata M., Yamazaki A., et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 2004, 64(16):5720-5727.
76. Moradi M.M., Carson L.F., Weinberg B., Haney A.F., Twiggs L.B., Ramakrishnan S. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer. Cancer 1993, 72(8):2433-2440.
77. Nagy J.A., Masse E.M., Herzberg K.T., et al. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res 1995, 55(2):360-368.
78. Wang Y., Qu Y., Niu X.L., Sun W.J., Zhang X.L., Li L.Z. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine 2011, 56(2):365-375.
79. Yagi H., Yotsumoto F., Miyamoto S. Heparin-binding epidermal growth factor-like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition. Mol Cancer Ther 2008, 7(10):3441-3451.
80. Nagy J.A., Meyers M.S., Masse E.M., Herzberg K.T., Dvorak H.F. Pathogenesis of ascites tumor growth: fibrinogen influx and fibrin accumulation in tissues lining the peritoneal cavity. Cancer Res 1995, 55(2):369-375.
81. Tanaka Y., Miyamoto S., Suzuki S.O., et al. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005, 11(13):4783-4792.
82. Buzzi S., Rubboli D., Buzzi G., Buzzi A.M., Morisi C., Pironi F. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 2004, 53(11):1041-1048.
83. Elias D., Gilly F., Boutitie F., et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010, 28(1):63-68.
84. Verwaal V.J., van Ruth S., de Bree E., et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003, 21(20):3737-3743.